{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:14Z","timestamp":1794925514559,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the frequency and characterize the clinical features of treatment-refractory myasthenia gravis in an Austrian cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient charts of 126 patients with generalized myasthenia gravis and onset between 2000 and 2016 were analyzed retrospectively. Patients were classified as treatment-refractory according to strict, predefined criteria. These mandated patients being at least moderately symptomatic (i.e., MGFA class III) or needing either maintenance immunoglobulins or plasma exchange therapy for at least 1 year in spite of two adequately dosed immunosuppressive drugs. Clinical features and outcome at last follow-up were compared to treatment-responsive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>14 out of 126 patients (11.1%) met these criteria of treatment-refractory myasthenia gravis. Treatment-refractory patients had more frequent clinical exacerbations and more often received rescue treatments or a further escalation of immunosuppressive therapies. They also remained more severely affected at last follow-up. An early onset of myasthenia gravis was associated with a higher risk for a refractory course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A small subgroup of patients with generalized myasthenia gravis do not respond sufficiently to standard therapies. Refractory disease has considerable implications for both patients and health care providers and highlights an unmet need for new treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-019-09667-5","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T11:04:03Z","timestamp":1576062243000},"page":"1004-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Frequency and clinical features of treatment-refractory myasthenia gravis"],"prefix":"10.1007","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-4572","authenticated-orcid":false,"given":"Jakob","family":"Rath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Tomschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Zulehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Zimprich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"key":"9667_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00508-012-0258-2","volume":"124","author":"H Cetin","year":"2012","unstructured":"Cetin H, F\u00fcl\u00f6p G, Zach H et al (2012) Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society. Wien Klin Wochenschr 124:763\u2013768. https:\/\/doi.org\/10.1007\/s00508-012-0258-2","journal-title":"Wien Klin Wochenschr"},{"key":"9667_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"9667_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx A, Pfister F, Schalke B et al (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875\u2013884. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.007","journal-title":"Autoimmun Rev"},{"key":"9667_CR4","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"9667_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","volume":"52","author":"HJ Oosterhuis","year":"1989","unstructured":"Oosterhuis HJ (1989) The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52:1121\u20131127. https:\/\/doi.org\/10.1136\/jnnp.52.10.1121","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9667_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"9667_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54:1041\u20131049. https:\/\/doi.org\/10.1002\/mus.25205","journal-title":"Muscle Nerve"},{"key":"9667_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI (2014) Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 15:167\u2013178. https:\/\/doi.org\/10.1097\/CND.0000000000000034","journal-title":"J Clin Neuromuscul Dis"},{"key":"9667_CR9","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"9667_CR10","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"key":"9667_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26114","author":"NM Engel-Nitz","year":"2018","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R et al (2018) Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.26114","journal-title":"Muscle Nerve"},{"key":"9667_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","volume":"15","author":"H Xin","year":"2019","unstructured":"Xin H, Harris LA, Aban IB, Cutter G (2019) Examining the Impact of refractory myasthenia gravis on healthcare resource utilization in the united states: analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol 15:376\u2013385. https:\/\/doi.org\/10.3988\/jcn.2019.15.3.376","journal-title":"J Clin Neurol"},{"key":"9667_CR13","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ (2013) Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 86:255\u2013260","journal-title":"Yale J Biol Med"},{"key":"9667_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3205\/000239","volume":"14","author":"SR Sudulagunta","year":"2016","unstructured":"Sudulagunta SR, Sepehrar M, Sodalagunta MB et al (2016) Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab. Ger Med Sci 14:12. https:\/\/doi.org\/10.3205\/000239","journal-title":"Ger Med Sci"},{"key":"9667_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"9667_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"key":"9667_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM et al (2012) Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45:909\u2013917. https:\/\/doi.org\/10.1002\/mus.23330","journal-title":"Muscle Nerve"},{"key":"9667_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"9667_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1468-1331.2010.03017.x","volume":"17","author":"Z-F Mao","year":"2010","unstructured":"Mao Z-F, Mo X-A, Qin C et al (2010) Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 17:913\u2013921. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03017.x","journal-title":"Eur J Neurol"},{"key":"9667_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09667-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09667-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T19:48:56Z","timestamp":1607543336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09667-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["9667"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09667-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,11]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No relevant conflicts of interest to disclose related to the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the local Ethics Committee of the Medical University of Vienna.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}}]}}